NEW YORK (GenomeWeb News) – VistaGen Therapeutics, a developer of bioassays for drug rescue projects, has signed a strategic financing agreement that will bring in proceeds of $36 million.

Under the agreement, VistaGen will provide 72 million shares of its restricted common stock at $.50 per share to the European subsidiary of Bergamo Acquisition Corp. The deal will provide Bergamo with a majority stake in VistaGen, which currently has around 20 million shares outstanding.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.